PCV13 + Hepatitis A Vaccine for Adults

Inclusion criteria

• Male or female subjects aged ≥50
• General good health as established by medical history and physical examination
• Written informed consent
• Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable.
• Available for all visits scheduled in this study.
• No previous Pnc vaccination
• No previous hepatitis A vaccine
• No other vaccines administered 30 days prior to or during the study

Exclusion criteria

• Previous pneumococcal or hepatitis A vaccination
• Immunization with any other vaccine (oral or parenteral) within 4 weeks prior to study start or planned vaccination during the study
• Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of vaccine; patients using oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent are excluded; inhaled or topical steroids are allowed
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
• Pregnancy or lactation
• Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever (fever is defined as body temperature of ≥38 °C).
• Alcohol or drug abuse
• Suspected non-compliance
• Use of any investigational drug within 30 days preceding the study vaccine, or planned use during the study period
• Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction based on the judgement of the investigator
• Employee at the investigational site, relative or spouse of the investigator
• Any other criteria which, in the investigator's opinion, would compromise the ability of the subject to participate in the study, the subject's well-being, or the outcome of the study